Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.
Laboratoire d'Immunologie et d'Immunomonitoring, CIC INSERM 1408 Vaccinologie, GIMAP EA3064, CHU de Saint-Etienne, Saint-Etienne, France.
S
S
Paul
Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France. xavier.roblin@chu-st-etienne.fr.
X
X
Roblin
Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Henri Poincaré University, Vandoeuvre-lès-Nancy, France.
L
L
Peyrin-Biroulet
D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha